Patents Assigned to National Institute of Immunology
  • Patent number: 9764015
    Abstract: The present invention in general relates Hemoglobin receptor or its part as a novel vaccine candidate against Leishmaniasis. Specifically, the present invention envisages HbR DNA for eliciting immune response in a mammal against Leishmaniasis. Additional aspect of the present invention is related to a vaccine composition for inducing immune response against Leishmaniasis in mammals. In a preferred aspect, the present invention relates to use of HbR-polypeptide as marker for diagnosis of Leishmania in kala-azar patients.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: September 19, 2017
    Assignees: National Institute of Immunology, Indian Institute of Chemical Biology
    Inventors: Amitabha Mukhopadhyay, Syamal Roy, Deepika Gupta, Rajan Guha, Ruchir Rastogi
  • Patent number: 9408900
    Abstract: The present invention relates to generation and high level expression of recombinant non-toxic of epsilon toxin of Clostridium perfringens as a recombinant vaccine against Clostridium perfringens infection and a process for producing the vaccine involving amplifying, cloning, transforming, incubating and purifying the recombinant non-toxic epsilon toxin protein. Thus in this invention, substitution mutation Y71G was executed in recombinant Etx and the recombinant EtxY71G protein was over-expressed in soluble form. Expressed protein was purified near homogeneity by DEAE sepharose anion exchange chromatography with high yield. Potential of rEtxY71G as a vaccine candidate was evaluated and found to be highly specific and immunogenic. The present invention is the first report for high level expression of non toxic rEtxY71G mutant protein of Clostridium perfringens. Upto 100 mg/L of highly immunogenic and homogeneous recombinant EtxY71G protein of 31 kDa was produced.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: August 9, 2016
    Assignee: National Institute of Immunology
    Inventors: Lalit Chander Garg, Keshav Gopal, Aparna Dixit
  • Publication number: 20150306195
    Abstract: The present invention in general relates Hemoglobin receptor or its part as a novel vaccine candidate against Leishmaniasis. Specifically, the present invention envisages HbR DNA for eliciting immune response in a mammal against Leishmaniasis. Additional aspect of the present invention is related to a vaccine composition for inducing immune response against Leishmaniasis in mammals. In a preferred aspect, the present invention relates to use of HbR-polypeptide as marker for diagnosis of Leishmania in kala-azar patients.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 29, 2015
    Applicants: INDIAN INSTITUTE OF CHEMICAL BIOLOGY, NATIONAL INSTITUTE OF IMMUNOLOGY
    Inventors: Amitabha MUKHOPADHYAY, Syamal ROY, Deepika GUPTA, Rajan GUHA, Ruchir RASTOGI
  • Publication number: 20140377228
    Abstract: The present invention is based on the findings that bone marrow (BM)-derived progenitor cells more specifically mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs) and uncommitted hematopoietic cells (lin?) are capable of regenerating liver in case of injury. The invention provides a method for treating genetic disorder like Alpha1-antitrypsin deficiency (A1-ATD) by administering BM derived Lin? cells in human mutant A1-AT expressing transgenic mouse model. The invention also provides the state of art for replacement of mutant host hepatocytes by transplanting wild-type uncommitted donor (lin?) cells.
    Type: Application
    Filed: December 17, 2013
    Publication date: December 25, 2014
    Applicant: NATIONAL INSTITUTE OF IMMUNOLOGY
    Inventors: Prakash Baliger, Jeffrey Teckman, Asok Mukhopadhyay
  • Publication number: 20140351966
    Abstract: The present invention relates to a new method of gene integration in cells comprising the steps of: preparation of a suspension of poly nucleotide fragments comprising the desired gene in a hypotonic solution; administration of said suspension to cells or tissues; and maintenance of the cells or tissues in vitro or in its normal physiological condition. The invention also relates to a method of generating transgenic animal.
    Type: Application
    Filed: December 4, 2013
    Publication date: November 27, 2014
    Applicant: National Institute of Immunology
    Inventors: Subeer Suhash Majumdar, Abul Usmani, Nirmalya Ganguli
  • Publication number: 20140348861
    Abstract: Synthetic peptides and peptide copolymers for amelioration of autoimmune neurological syndrome, inflammatory and/or demyelinating conditions such as encephalomyletis are provided herein. The synthetic peptides and peptide copolymers as disclosed are obtained by substitution of at least one alpha amino acid by beta amino acid and/or ?3-homo amino acid.
    Type: Application
    Filed: May 3, 2012
    Publication date: November 27, 2014
    Applicant: NATIONAL INSTITUTE OF IMMUNOLOGY
    Inventors: Avadhesha Surolia, Ravi Kant Gautam, Vishnu Kumar Dwivedi, Sarika Gupta
  • Publication number: 20140242117
    Abstract: The present investigation relates to entrapment of carbohydrate antigen such as Vi polysaccharide of Salmonella typhi in poly (DL) lactide (PDLLA) and polylactide-co-glycolide (PLGA) polymer particles. The formulated product not only elicits primary antibody titers from single dose application but also evokes memory antibody titer against the T independent antigen.
    Type: Application
    Filed: May 29, 2012
    Publication date: August 28, 2014
    Applicant: National Institute of Immunology
    Inventors: Anish Chakkumkal, Amulya Kumar Panda
  • Publication number: 20130259948
    Abstract: The present invention relates to a novel effective dry powder vaccine formulation that increases the immune response in the host. The formulation comprises of an antigen entrapped into a polymer particle, coated with alum, finally spray dried into a dry powder. This formulation is used to elicit long lasting higher antibody titers than alum adsorbed antigen or admixture of polymer entrapped antigen and alum.
    Type: Application
    Filed: September 20, 2011
    Publication date: October 3, 2013
    Applicant: NATIONAL INSTITUTE OF IMMUNOLOGY
    Inventors: Amulya Kumar Panda, Anish Chakkunkal, Dinesh Giri Goswami
  • Publication number: 20130245228
    Abstract: The present invention relates to a method of in vitro isolation of buffalo ?-caesin promoter (buCSN2) along with the regions exon1, intron1 and exon2 from the genomic DNA in vitro (Bubalus bubalis) and its functional activity in using mammary cell line. The novel buffalo ?-caesin promoter along with exon1, intron1 and exon2 is isolated and cloned upstream of the Enhanced Green flourescence protein (EGFP) gene and sequenced. The transfection of the DNA construct resulted into production of EGFP protein in mammary cell lines, confirming bioactivity of this newly isolated buffalo promoter sequence. More specifically, the present invention relates to isolation, cloning, sequencing and functional analysis of the buffalo ?-casein promoter in vitro using mammary cell line.
    Type: Application
    Filed: May 20, 2013
    Publication date: September 19, 2013
    Applicant: National Institute of Immunology
    Inventors: Subeer Suhash Majumdar, Nirmalya Ganguli, Abul Usmani
  • Publication number: 20130183344
    Abstract: The present invention relates to generation and high level expression of recombinant non-toxic of epsilon toxin of Clostridium perfringens as a recombinant vaccine against Clostridium perfringens infection and a process for producing the vaccine involving amplifying, cloning, transforming, incubating and purifying the recombinant non-toxic epsilon toxin protein. Thus in this invention, substitution mutation Y71G was executed in recombinant Etx and the recombinant EtxY71G protein was over-expressed in soluble form. Expressed protein was purified near homogeneity by DEAE sepharose anion exchange chromatography with high yield. Potential of rEtxY71G as a vaccine candidate was evaluated and found to be highly specific and immunogenic. The present invention is the first report for high level expression of non toxic rEtxY71G mutant protein of Clostridium perfringens. Upto 100 mg/L of highly immunogenic and homogeneous recombinant EtxY71G protein of 31 kDa was produced.
    Type: Application
    Filed: July 1, 2011
    Publication date: July 18, 2013
    Applicant: NATIONAL INSTITUTE OF IMMUNOLOGY
    Inventors: Lalit Chander Garg, Keshav Gopal, Aparna Dixit
  • Patent number: 8426362
    Abstract: A supramolecular insulin assembly and supramolecular exendin-4 assembly, which is useful as a protein therapeutic agent for the treatment of metabolic disorders particularly diabetes. The supramolecular assemblies disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising the supramolecular assembly.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: April 23, 2013
    Assignees: National Institute of Immunology, Indian Institute of Science
    Inventors: Avadhesha Surolia, Sarika Gupta, Mahendra Pal Singh, Tandrika Chattopadhyay
  • Publication number: 20120284809
    Abstract: The present invention relates the function of Dickkopf 3 (Dkk3 ) in testis using shRNA mediated knock down model. Specifically, the present invention provides knock down model comprising reduction in Dkk3 activity. The knock down model of Dkk3 consisting of non human vertebrates which have, incorporated in their genome, shRNA construct targeting mammalian Dkk3 gene exhibits low testis weight, low sperm count and has low litter size. The knock down model displays disrupted seminiferous tubules and are subfertile. The present invention model has a role in sex determination as its interruption leads to sex reversal of XY gonads, converting males to females. Sex reversal role of Dkk3 knock down model can find its utility in agricultural applications. The present invention describes Dkk3 as a dual function protein which is associated with sex determination as well as is essential for the process of spermatogenesis.
    Type: Application
    Filed: May 6, 2011
    Publication date: November 8, 2012
    Applicant: National Institute of Immunology
    Inventors: Subeer S. Majumdar, Deepika Sharma, Neerja Wadhwa
  • Publication number: 20120264814
    Abstract: The present invention relates to a method of in vitro isolation of buffalo ?-caesin promoter (buCSN2) along with the regions of exon1, intron1 and exon2 from the genomic DNA in vitro (Bubalus bubalis) and its functional activity in using mammary cell line. The novel buffalo ?-caesin promoter along with exon1, intron1 and exon2 is isolated and cloned upstream of the Enhanced Green flourescence protein (EGFP) gene and sequenced. The transfection of the DNA construct resulted into production of EGFP protein in mammary cell lines, confirming bioactivity of this newly isolated buffalo promoter sequence. More specifically, the present invention relates to isolation, cloning, sequencing and functional analysis of the buffalo ?-casein promoter in vitro using mammary cell line.
    Type: Application
    Filed: June 16, 2011
    Publication date: October 18, 2012
    Applicant: NATIONAL INSTITUTE OF IMMUNOLOGY
    Inventors: Subeer Suhash MAJUMDAR, Nirmalya Ganguli, Abul Usmani
  • Patent number: 8268342
    Abstract: The present invention relates to a process for preparation of a biodegradable polymer scaffold using biodegradable polymer, surfactant and alcohol. The biodegradable polymer scaffold obtained from the process disclosed is useful for tissue engineering, therapeutic compound delivery and/or wound dressing.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: September 18, 2012
    Assignee: National Institute of Immunology
    Inventors: Amulya Kumar Panda, Rajmohan Gopimohan, Anish Chakkunkal
  • Patent number: 8227591
    Abstract: The present invention relates to the field of cancer therapy. More specifically, the invention relates to use of certain nucleotide sequences for the treatment of cancer.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: July 24, 2012
    Assignee: National Institute of Immunology
    Inventor: Anil Kumar Suri
  • Patent number: 8148321
    Abstract: The present disclosure relates to a novel enzymatic approach according to the invention using an unprecedented sortase-catalyzed transpeptidation reaction between a substrate comprising LPXTG (SEQ ID NO: 11) peptide motif and biomolecules such as aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids, polyamines; nucleic acids or derivatives thereof; or any molecule having such moieties; or any compound having such moieties to obtain a bioconjugates useful for target delivery of a compound. The present disclosure provides bioconjugates obtained by the novel sortase catalysed transpeptidedation reaction.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: April 3, 2012
    Assignee: National Institute of Immunology
    Inventors: Rajendra Prasad Roy, Sharmishtha Samantaray
  • Patent number: 8143007
    Abstract: The present invention provides oligonucleotides for detection of rearrangement of immunoglobulin genes for identifying clonality of cells, cancer cells, hypermutation in immunoglobulin gene, antibody isotype producing cell and/or assaying B cell repertoire in a sample. The oligonucleotides disclosed in the present invention are very specific to the immunoglobulin genes.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: March 27, 2012
    Assignee: National Institute of Immunology
    Inventors: Sehgal Devinder, Rohatgi Soma
  • Publication number: 20120016014
    Abstract: The present invention provides benzothiophene carboxamide compounds of formula I, their polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, which are useful as COX-2 inhibitors and PfENR inhibitors. The invention further relates to pharmaceutical compositions containing such compounds and methods for their application as COX-2 inhibitors for treating inflammation and pain and PfENR inhibitors for use as anti-malarials.
    Type: Application
    Filed: July 14, 2011
    Publication date: January 19, 2012
    Applicants: INDIAN INSTITUTE OF SCIENCE, NATIONAL INSTITUTE OF IMMUNOLOGY
    Inventors: Avadhesha Surolia, Tanushree Banerjee, Namita Surolia, Neha Kapoor
  • Publication number: 20120017289
    Abstract: The present invention provides a novel method of generating knock down models by electroporation of shRNA construct into the testis. The present invention provides an ethically superior, non-surgical, user friendly rapid method for the generation of permanent lines of shRNA knock down non human vertebrates. This invention is ethically superior as it does not involve any loss of animal life and drastically minimizes the production time and use of animals. Current techniques for making knockout models are cumbersome, require trained personnel, costly infrastructure and require hundreds of eggs collected after killing several females. In contrast, this method neither involves any costly infrastructure nor requires trained personnel. The invention also relates to the quick incorporation of shRNA gene construct into the germline of a species so that shRNA is inheritable.
    Type: Application
    Filed: October 1, 2010
    Publication date: January 19, 2012
    Applicant: National Institute of Immunology
    Inventors: Subeer Suhash Majumdar, Deepika Sharma, Neerja Wadhwa
  • Publication number: 20110178142
    Abstract: The present invention provides a pharmaceutical composition comprising 3-{5-[4-Oxo-2-thioxo-3-(3-trifluoromethyl-phenyl)-thiazolidin-5-ylidenemethyl]-furan-2-yl}-benzoic acid or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients for therapeutic or prophylactic treatment of bacterial infections and diseases associated thereof.
    Type: Application
    Filed: October 13, 2009
    Publication date: July 21, 2011
    Applicant: National Institute of Immunology
    Inventors: Avadhesha Surolia, Tushar Beuria Kant, Panda Dulal